NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES - Seite 2
About Type 1 Diabetes
Type 1 Diabetes is an autoimmune disease which is foreseen to affect 25 million people in the world by the year 2020 with growing incidence worldwide (+3%pa). Source WHO. This
disease may cause severe and even life threatening complications and has no curative treatment. Patients have to monitor their glycaemia throughout the day and are treated with multiple insulin
injections over their lifetime.
About Neovacs Technology
Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of
an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal
antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its pharmacological effects. Several autoimmune and inflammatory diseases (Type 1 diabetes,
systemic lupus erythematosus, psoriasis, etc.) are characterized by a disorder of cytokines that are found produced in excess (ex: IFNalpha). This overproduction will promote inflammation and
dysregulation of the immune system.
About Neovacs
Listed on Euronext Growth Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical
development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access
to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
LIFESCI ADVISORS- Investor Relations / Financial Communications
Chris Maggos
chris@lifesciadvisors.com
Lesen Sie auch
+41 79 367 6254
[1] Non-obese Diabetic (NOD), Leiter, Curr Protoc Mouse Biol. 2013
[2] Langerhans islets or pancreatic islets: cells capable of producing insulin
[3] Lauwerys et al., Arthritis & Rheumatism 2013 ; Ducreux et al., Rheumatology 2016
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire